Cullinan Therapeutics Shares Are Trading Higher. The Company This Week Announced That Clinical Data From Its Phase 1 Trial of CLN-619 in Patients With Advanced Solid Tumors Will Be Presented at the 2024 ASCO Annual Meeting.
Cullinan Therapeutics Shares Are Trading Higher. The Company This Week Announced That Clinical Data From Its Phase 1 Trial of CLN-619 in Patients With Advanced Solid Tumors Will Be Presented at the 2024 ASCO Annual Meeting.
Cullinan Therapeutics的股價正在走高。該公司本週宣佈，將在2024年ASCO年會上公佈其針對晚期實體瘤患者的 CLN-619 1期試驗的臨床數據。
Cullinan Therapeutics Shares Are Trading Higher. The Company This Week Announced That Clinical Data From Its Phase 1 Trial of CLN-619 in Patients With Advanced Solid Tumors Will Be Presented at the 2024 ASCO Annual Meeting.
Cullinan Therapeutics的股價正在走高。該公司本週宣佈，將在2024年ASCO年會上公佈其針對晚期實體瘤患者的 CLN-619 1期試驗的臨床數據。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。